Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Tasigna“
Suchtreffer
Begriffe & Kennungen
Tasigna · 4.5 · Rifampicin, a potent CYP3A4 inducer, decreases nilotinib Cmax by 64% and reduces nilotinib AUC by 80%. Rifampi
Eintrag öffnenTasigna · 4.5 · Substances that may decrease nilotinib serum concentrations
Eintrag öffnenTasigna · 4.5 · Substances that may have their systemic concentration altered by nilotinib
Eintrag öffnenTasigna · 4.5 · Substances that may increase nilotinib serum concentrations
Eintrag öffnenTasigna · 4.5 · Tasigna may be given in combination with haematopoietic growth factors such as erythropoietin or granulocyte c
Eintrag öffnenTasigna · 4.5 · The absorption and bioavailability of nilotinib are increased if it is taken with food, resulting in a higher
Eintrag öffnenTasigna · 4.5 · The combination of nilotinib with those statins that are mainly eliminated by CYP3A4, may increase the potenti
Eintrag öffnenTasigna · 4.5 · The concomitant administration of other medicinal products that induce CYP3A4 (e.g. phenytoin, carbamazepine,
Eintrag öffnenTasigna · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenTasigna · 4.8 Undesirable effects · 1
Eintrag öffnenTasigna · 4.8 · 13 Metabolism and nutrition disorders Common: Electrolyte imbalance (including hypomagnesaemia, hyperkalaemia,
Eintrag öffnenTasigna · 4.8 · 14 Gastrointestinal disorders Very common: Nausea, upper abdominal pain, constipation, diarrhoea, vomiting Com
Eintrag öffnenTasigna · 4.8 · 15 Investigations Very common: Alanine aminotransferase increased, lipase increased Common: Haemoglobin decrea
Eintrag öffnenTasigna · 4.8 · Adverse reactions from clinical studies and post-marketing reports (Table 3) are listed by MedDRA system organ
Eintrag öffnenTasigna · 4.8 · Description of selected adverse reactions
Eintrag öffnenTasigna · 4.8 · Growth retardation in paediatric population In a study conducted in the CML paediatric population, with a medi
Eintrag öffnenTasigna · 4.8 · Hepatitis B reactivation Hepatitis B reactivation has been reported in association with BCR-ABL TKIs. Some cas
Eintrag öffnenTasigna · 4.8 · Infections and infestations Very common: Upper respiratory tract infection (including pharyngitis, nasopharyng
Eintrag öffnenTasigna · 4.8 · Paediatric population
Eintrag öffnenTasigna · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnen